Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin

Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2010-11, Vol.1 (6), p.1013-1017
Main Authors: WONG, ANGELA M, ZHANG, YANJUNG, KESLER, KELLY, DENG, MAX, BURHENN, LUCAS, WANG, DAVID, MORO, AUNE, LI, ZHAOPING, HEBER, DAVID
Format: Article
Language:English
Subjects:
inflammation
nuclear factor-κB
prostate cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353
cites cdi_FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353
container_end_page 1017
container_issue 6
container_start_page 1013
container_title Experimental and therapeutic medicine
container_volume 1
creator WONG, ANGELA M
ZHANG, YANJUNG
KESLER, KELLY
DENG, MAX
BURHENN, LUCAS
WANG, DAVID
MORO, AUNE
LI, ZHAOPING
HEBER, DAVID
description Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. Three groups of 8 SCID mice bearing human prostate cancer xenografts (LAPC-4) were administered either RRE containing 0.02 mg/g oridonin, pure oridonin at a dose of 0.02 mg/g, or pure oridonin at a dose of 0.1 mg/g, by gavage for 5 days/week for 4 weeks. RRE and pure oridonin at 0.1 mg/g inhibited tumor growth to a similar extent, while oridonin at a dose of 0.02 mg/g did not. Therefore, in comparison to RRE, five times more pure oridonin was required to obtain equivalent prostate xenograft growth inhibition. Since the nuclear factor-κB signaling pathway and inflammation are implicated in prostate carcinogenesis, gene microarray analysis was conducted and demonstrated activation of genes by RRE that was not evident with oridonin treatment alone. This study demonstrated that genomic methods and xenograft studies are capable of demonstrating the benefits of the synergy of whole plant extracts rather than active ingredients isolated and purified as drugs.
doi_str_mv 10.3892/etm.2010.145
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3445985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22993634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353</originalsourceid><addsrcrecordid>eNpVUU1LxDAUDKKorN48y7t5sWvSNP3wIIj4BYIg3kPavKyRbbIktbhn_7gpq4uGwHth5k2SGUJOGJ3zuskvcOjnOU0nVogdcsiqJs8YZWL3p6dNzQ7IcYzvNC1RsroW--Qgz5uGl7w4JF_36HxvO1BOg3Uw2tEDjlaj6xC8gbh2GBbrqVXwhqFVS8DPIahugM73KxVQw-DBDhF6HwdIgB0xaS0SYtENl_CiWu2jVRA-WowdughjnIMPVntn3RHZM2oZ8finzsjr3e3rzUP29Hz_eHP9lHUFK4fM8Ko1dVOlyhlvjBYVpl0arouy5kIwUZYM87plVUVpVRU5oxopN8wUXPAZudrIrj7aHnV6RvrFUq6C7VVYS6-s_I84-yYXfpS8KERTTwLnG4Eu-BgDmu0so3KKQ6Y45BSHTHEk-unf-7bkX_MT4WxDiKvkfvIibjlJKKMso-WUJuff1dmU_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin</title><source>PubMed Central</source><creator>WONG, ANGELA M ; ZHANG, YANJUNG ; KESLER, KELLY ; DENG, MAX ; BURHENN, LUCAS ; WANG, DAVID ; MORO, AUNE ; LI, ZHAOPING ; HEBER, DAVID</creator><creatorcontrib>WONG, ANGELA M ; ZHANG, YANJUNG ; KESLER, KELLY ; DENG, MAX ; BURHENN, LUCAS ; WANG, DAVID ; MORO, AUNE ; LI, ZHAOPING ; HEBER, DAVID</creatorcontrib><description>Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. Three groups of 8 SCID mice bearing human prostate cancer xenografts (LAPC-4) were administered either RRE containing 0.02 mg/g oridonin, pure oridonin at a dose of 0.02 mg/g, or pure oridonin at a dose of 0.1 mg/g, by gavage for 5 days/week for 4 weeks. RRE and pure oridonin at 0.1 mg/g inhibited tumor growth to a similar extent, while oridonin at a dose of 0.02 mg/g did not. Therefore, in comparison to RRE, five times more pure oridonin was required to obtain equivalent prostate xenograft growth inhibition. Since the nuclear factor-κB signaling pathway and inflammation are implicated in prostate carcinogenesis, gene microarray analysis was conducted and demonstrated activation of genes by RRE that was not evident with oridonin treatment alone. This study demonstrated that genomic methods and xenograft studies are capable of demonstrating the benefits of the synergy of whole plant extracts rather than active ingredients isolated and purified as drugs.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2010.145</identifier><identifier>PMID: 22993634</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>inflammation ; nuclear factor-κB ; prostate cancer</subject><ispartof>Experimental and therapeutic medicine, 2010-11, Vol.1 (6), p.1013-1017</ispartof><rights>Copyright © 2010, Spandidos Publications</rights><rights>Copyright © 2010, Spandidos Publications 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353</citedby><cites>FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445985/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445985/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22993634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WONG, ANGELA M</creatorcontrib><creatorcontrib>ZHANG, YANJUNG</creatorcontrib><creatorcontrib>KESLER, KELLY</creatorcontrib><creatorcontrib>DENG, MAX</creatorcontrib><creatorcontrib>BURHENN, LUCAS</creatorcontrib><creatorcontrib>WANG, DAVID</creatorcontrib><creatorcontrib>MORO, AUNE</creatorcontrib><creatorcontrib>LI, ZHAOPING</creatorcontrib><creatorcontrib>HEBER, DAVID</creatorcontrib><title>Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. Three groups of 8 SCID mice bearing human prostate cancer xenografts (LAPC-4) were administered either RRE containing 0.02 mg/g oridonin, pure oridonin at a dose of 0.02 mg/g, or pure oridonin at a dose of 0.1 mg/g, by gavage for 5 days/week for 4 weeks. RRE and pure oridonin at 0.1 mg/g inhibited tumor growth to a similar extent, while oridonin at a dose of 0.02 mg/g did not. Therefore, in comparison to RRE, five times more pure oridonin was required to obtain equivalent prostate xenograft growth inhibition. Since the nuclear factor-κB signaling pathway and inflammation are implicated in prostate carcinogenesis, gene microarray analysis was conducted and demonstrated activation of genes by RRE that was not evident with oridonin treatment alone. This study demonstrated that genomic methods and xenograft studies are capable of demonstrating the benefits of the synergy of whole plant extracts rather than active ingredients isolated and purified as drugs.</description><subject>inflammation</subject><subject>nuclear factor-κB</subject><subject>prostate cancer</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LxDAUDKKorN48y7t5sWvSNP3wIIj4BYIg3kPavKyRbbIktbhn_7gpq4uGwHth5k2SGUJOGJ3zuskvcOjnOU0nVogdcsiqJs8YZWL3p6dNzQ7IcYzvNC1RsroW--Qgz5uGl7w4JF_36HxvO1BOg3Uw2tEDjlaj6xC8gbh2GBbrqVXwhqFVS8DPIahugM73KxVQw-DBDhF6HwdIgB0xaS0SYtENl_CiWu2jVRA-WowdughjnIMPVntn3RHZM2oZ8finzsjr3e3rzUP29Hz_eHP9lHUFK4fM8Ko1dVOlyhlvjBYVpl0arouy5kIwUZYM87plVUVpVRU5oxopN8wUXPAZudrIrj7aHnV6RvrFUq6C7VVYS6-s_I84-yYXfpS8KERTTwLnG4Eu-BgDmu0so3KKQ6Y45BSHTHEk-unf-7bkX_MT4WxDiKvkfvIibjlJKKMso-WUJuff1dmU_w</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>WONG, ANGELA M</creator><creator>ZHANG, YANJUNG</creator><creator>KESLER, KELLY</creator><creator>DENG, MAX</creator><creator>BURHENN, LUCAS</creator><creator>WANG, DAVID</creator><creator>MORO, AUNE</creator><creator>LI, ZHAOPING</creator><creator>HEBER, DAVID</creator><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20101101</creationdate><title>Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin</title><author>WONG, ANGELA M ; ZHANG, YANJUNG ; KESLER, KELLY ; DENG, MAX ; BURHENN, LUCAS ; WANG, DAVID ; MORO, AUNE ; LI, ZHAOPING ; HEBER, DAVID</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>inflammation</topic><topic>nuclear factor-κB</topic><topic>prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WONG, ANGELA M</creatorcontrib><creatorcontrib>ZHANG, YANJUNG</creatorcontrib><creatorcontrib>KESLER, KELLY</creatorcontrib><creatorcontrib>DENG, MAX</creatorcontrib><creatorcontrib>BURHENN, LUCAS</creatorcontrib><creatorcontrib>WANG, DAVID</creatorcontrib><creatorcontrib>MORO, AUNE</creatorcontrib><creatorcontrib>LI, ZHAOPING</creatorcontrib><creatorcontrib>HEBER, DAVID</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WONG, ANGELA M</au><au>ZHANG, YANJUNG</au><au>KESLER, KELLY</au><au>DENG, MAX</au><au>BURHENN, LUCAS</au><au>WANG, DAVID</au><au>MORO, AUNE</au><au>LI, ZHAOPING</au><au>HEBER, DAVID</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>1</volume><issue>6</issue><spage>1013</spage><epage>1017</epage><pages>1013-1017</pages><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. Three groups of 8 SCID mice bearing human prostate cancer xenografts (LAPC-4) were administered either RRE containing 0.02 mg/g oridonin, pure oridonin at a dose of 0.02 mg/g, or pure oridonin at a dose of 0.1 mg/g, by gavage for 5 days/week for 4 weeks. RRE and pure oridonin at 0.1 mg/g inhibited tumor growth to a similar extent, while oridonin at a dose of 0.02 mg/g did not. Therefore, in comparison to RRE, five times more pure oridonin was required to obtain equivalent prostate xenograft growth inhibition. Since the nuclear factor-κB signaling pathway and inflammation are implicated in prostate carcinogenesis, gene microarray analysis was conducted and demonstrated activation of genes by RRE that was not evident with oridonin treatment alone. This study demonstrated that genomic methods and xenograft studies are capable of demonstrating the benefits of the synergy of whole plant extracts rather than active ingredients isolated and purified as drugs.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>22993634</pmid><doi>10.3892/etm.2010.145</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-0981
ispartof Experimental and therapeutic medicine, 2010-11, Vol.1 (6), p.1013-1017
issn 1792-0981
1792-1015
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3445985
source PubMed Central
subjects inflammation
nuclear factor-κB
prostate cancer
title Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T04%3A28%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genomic%20and%20in%20vivo%20evidence%20of%20synergy%20of%20a%20herbal%20extract%20compared%20to%20its%20most%20active%20ingredient:%20Rabdosia%20rubescens%20vs.%20oridonin&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=WONG,%20ANGELA%20M&rft.date=2010-11-01&rft.volume=1&rft.issue=6&rft.spage=1013&rft.epage=1017&rft.pages=1013-1017&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2010.145&rft_dat=%3Cpubmed_cross%3E22993634%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-f37bf897f373139fd57e57e6f3d46835515661e28b17700774210de03f1f4353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22993634&rfr_iscdi=true